ArticleScientific reports2025
ALDH18A1 has carcinogenic functions and regulates alternative splicing events of DNA repair-related genes in esophageal carcinoma cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal carcinoma (ESCA) is a common tumor in the digestive system, resulting in approximately 300,000 death worldwide every year. ALDH18A1, a potential RNA binding protein (RBP), is significantly overexpressed as in ESCA, while its functions and mechanism is unclear. In this study, we silenced ALDH18A1 in KYSE150 cells using small interfering RNA (siALDH18A1), and evaluated its effect on cell characteristics. Finally, we conducted whole transcriptome sequencing (RNA-seq) and RNA immunoprecipitation (iRIP-seq) experiments to explore the downstream targets of ALDH18A1, and verified their change patterns using quantitative polymerase chain reaction. We found that ALDH18A1 exhibited a high expression level in ESCA patients using online database. The proliferation, invasion, and migration abilities of KYSE150 cells were significantly inhibited in siALDH18A1 samples. Through the investigation of RNA-seq data, we found that ALDH18A1 globally regulates the expression and alternative splicing profiles of KYSE150 cells by identifying 437 differentially expressed genes (DEGs) and 1071 ALDH18A1-regulated AS events (RASEs), respectively. The functions of RASE genes (RASGs) were enriched in pathways such as DNA repair and gene expression. In addition, through the integration analysis of iRIP-seq data and DEGs, we found that ALDH18A1 bound to and regulated the expression of 59 DEGs, including LAMB3 and IL1B, which were verified by RT-qPCR experiment. In addition, we performed an overlap analysis between the genes bound by ALDH18A1 and RASGs and found 339 bound RASGs. The functional enrichment of these genes revealed pathways such as DNA repair, cell proliferation, and DNA damage response. Among them, we found significant alternative splicing events of MTA1, which were confirmed by PCR experiments. In summary, our study comprehensively explored the functions and downstream targets of ALDH18A1 in ESCA cells, highlighting the molecular mechanism of ALDH18A1 on the carcinogenic characteristics of ESCA. The identified molecular targets, especially DNA repair-related genes, can serve as potential therapeutic targets for future ESCA treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.